InvestorsHub Logo
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: genisi post# 374

Tuesday, 06/16/2009 6:34:08 PM

Tuesday, June 16, 2009 6:34:08 PM

Post# of 3997
I would think Shire stands to gain the most (Replagal and their Gaucher candidate). I think Genzyme's Orphan exclusivity is running down but I haven't kept up to know if Shire is planning on entering the US market with Replagal. I wonder if they could gain some compassionate use sales if the shortage persists.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News